Mortality and Morbidity in Adults With Rheumatic Heart Disease

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, JUNE 5, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8258?guestAccessKey=7126055e-42d5-4b76-961b-299607f90b1f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060524

 

About The Study: Mortality in rheumatic heart disease is high and is correlated with the severity of valve disease. Valve surgery and valvuloplasty were associated with substantially lower mortality. Study findings suggest a greater need to improve access to surgical and interventional care, in addition to the current approaches focused on antibiotic prophylaxis and anticoagulation.

Corresponding Author: To contact the corresponding author, Ganesan Karthikeyan, M.D., D.M., email karthik2010@gmail.com.

 

(doi:10.1001/jama.2024.8258)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Service Dogs for Veterans and Military Members With Posttraumatic Stress Disorder

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 4, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.14686?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This nonrandomized controlled trial found that compared with usual care alone, partnership with a trained psychiatric service dog was associated with lower posttraumatic stress disorder (PTSD) symptom severity and higher psychosocial functioning in veterans. Psychiatric service dogs may be an effective complementary intervention for military service–related PTSD. 

Corresponding Author: To contact the corresponding author, Marguerite E. O’Haire, Ph.D., email maggieohaire@arizona.edu.

 

(doi:10.1001/jamanetworkopen.2024.14686)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, JUNE 4, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.14582?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=060424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This population-based cohort study of men with prostate cancer suggests that higher county-level prevalence of prostate-specific antigen (PSA) screening was associated with lower odds of advanced disease, all-cause mortality, and prostate cancer–specific mortality. Associations varied by age, race and ethnicity, and U.S. Census region. 

Corresponding Author: To contact the corresponding author, Hari S. Iyer, Sc.D., M.P.H., email hari.iyer@rutgers.edu.

 

(doi:10.1001/jamanetworkopen.2024.14582)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Lowering Fecal Immunochemical Test Positivity Threshold vs Multitarget Stool RNA Testing for Colorectal Cancer Screening

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, SATURDAY, JUNE 1, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.9289?guestAccessKey=e9d1d41d-b503-4d1c-8d00-6d5666d0c76f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060124

 

About The Study: This study found that comparable levels of sensitivity and specificity as reported for the multitarget stool RNA (mt-sRNA) test in the colorectal cancer (CRC)-PREVENT study could be achieved by lowering the fecal immunochemical test positivity threshold, without additional mt-sRNA testing. The findings are similar to previous observations for multitarget stool DNA testing.

Corresponding Author: To contact the corresponding author, Hermann Brenner, M.D., M.P.H., email h.brenner@dkfz.de.

 

(doi:10.1001/jama.2024.9289)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial and Ethnic Disparities in Medicaid Disenrollment After the End of the COVID-19 Public Health Emergency

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.1503?guestAccessKey=24afafdf-b285-429d-adcb-d5689f7f1018&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060324

No Comments

Filed under:

Weight Indices, Cognition, and Mental Health From Childhood to Early Adolescence

Posted by Jim Michalski

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 3, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1379?guestAccessKey=a2bee6aa-d8f1-4b9e-bedd-e84ecfd92b92&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060324

 

About The Study: Lower cognitive performance and greater psychopathology at baseline were associated with increased weight gain as children entered adolescence, and higher baseline body mass index was associated with more depressive symptoms over time. These longitudinal findings highlight the importance of cognitive and mental health to children’s healthy weight development and suggest that clinicians should monitor children with overweight or obesity for increased depression problems.

Corresponding Author: To contact the corresponding author, Tamara Hershey, Ph.D., email tammy@wustl.edu.

 

(doi:10.1001/jamapediatrics.2024.1379)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Clinical Outcomes After Admission of Patients With COVID-19 to Skilled Nursing Facilities

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, JUNE 3, 2024

Media advisory: The full study and commentary are linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.1079?guestAccessKey=b5d0392e-0e9e-4985-9376-0b48c27db090&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060324

 

About The Study: The results of this cohort study suggest that admission of COVID-19–positive patients into skilled nursing facilities early in the pandemic was associated with preventable COVID-19 cases and mortality among residents, particularly in facilities with potential staff and personal protective equipment shortages. The findings speak to the importance of equipping skilled nursing facilities to adhere to infection-control best practices as they continue to face COVID-19 strains and other respiratory diseases. 

Corresponding Author: To contact the corresponding author, Michael L. Barnett, M.D., M.S., email mbarnett@hsph.harvard.edu.

 

(doi:10.1001/jamainternmed.2024.1079)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Assessing the Environmental and Downstream Human Health Impacts of Decentralizing Cancer Care

Posted by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 9:44 A.M. (ET), MONDAY, JUNE 3, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.2744?guestAccessKey=82625958-1bc1-4dbf-bcad-931ea8d66656&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060324

 

About The Study: This cohort study found that using decentralization through telemedicine and local care may substantially reduce cancer care’s greenhouse gas emissions; this corresponds to small reductions in human mortality. 

Corresponding Author: To contact the corresponding author, Gregory A. Abel, M.D., M.P.H., email gregory_abel@dfci.harvard.edu.

 

(doi:10.1001/jamaoncol.2024.2744)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Geographic Distribution of Clinical Trials for Advanced-Stage Cancer

Posted by Jim Michalski

JAMA Oncology

EMBARGOED FOR RELEASE: 10 A.M. (ET), MONDAY, JUNE 3, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.1690?guestAccessKey=6f68fd34-2884-4496-b5bf-5e2bc1ddde9f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060324

 

About The Study: This quality improvement analysis of clinical trials for metastatic breast, lung, colon, pancreatic, and prostate cancers found that a large proportion of the U.S. population lived within 30 miles of a clinical trial site. This finding suggests that while many clinical trials are available, they are not evenly distributed across the country and may not be accessible to all individuals, particularly racial and ethnic minority individuals. This disparity in access to clinical trials raises important questions about equity and fairness in the distribution of health care resources and opportunities for treatment. 

Corresponding Author: To contact the corresponding author, Wade T. Swenson, M.D., M.P.H., M.B.A., email drswenson@lakewoodhealthsystem.com; wade@ruralcancer.org.

 

 (doi:10.1001/jamaoncol.2024.1690)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3:45 P.M. ET, FRIDAY, MAY 31, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.10613?guestAccessKey=4a907c26-6d2e-46e7-94b1-d0b5670ff18a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053124

 

About The Study: Ivonescimab plus chemotherapy significantly improved progression-free survival with tolerable safety profile in patients with non–small cell lung cancer who previously underwent EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and may offer a new treatment option for patients with TKI resistance. 

 

Quote from corresponding author Li Zhang, M.D.:

“For patients with non-small cell lung cancer whose illness has progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, especially the third generation TKIs, optimal treatment options remain limited.

“This randomized, placebo-controlled phase 3 study demonstrated ivonescimab plus chemotherapy significantly improved progression-free survival (7.1 vs 4.8 months) compared with chemotherapy alone in TKI-treated non-small cell lung cancer.

“Based on the results of this study, ivonescimab has been approved in China as a new treatment option for those patients. An international multi-center study of this treatment regimen is ongoing.”

Contact information for Li Zhang, M.D.: email zhangli@sysucc.org.cn.

 

(doi:10.1001/jama.2024.10613)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Stepped Palliative Care for Patients With Advanced Lung Cancer

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, JUNE 2, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.10398?guestAccessKey=6d013912-6999-410b-8311-aa32d7baabba&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060224

 

About The Study: A stepped-care model, with palliative care visits occurring only at key points in patients’ cancer trajectories and using a decrement in quality of life to trigger more intensive palliative care exposure, resulted in fewer palliative care visits without diminishing the benefits for patients’ quality of life. While stepped palliative care was associated with fewer days in hospice, it is a more scalable way to deliver early palliative care to enhance patient-reported outcomes. 

 

Quote from corresponding author Jennifer S. Temel, M.D.:

“This study demonstrates that early palliative care can be effectively tailored to a patient’s cancer and care needs to maximize their quality of life while utilizing fewer palliative care resources. Implementing this patient-centered approach to delivering early palliative care will allow more patients to access essential early palliative care services.

“These findings are especially salient as patients with advanced cancer are now living longer while being treated with life-long cancer therapies, so a tailored palliative care model enables greater dissemination of palliative care services while ensuring patients receive the care they need when they need it.

“This research continues to grow the evidence base that early palliative care is a necessary and integral component of cancer care for patients diagnosed with advanced cancer and provides data on how to increase the number of patients who can access this essential service.”  

Contact information for Jennifer S. Temel, M.D.: email jtemel@mgh.harvard.edu.

 

(doi:10.1001/jama.2024.10398)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Tirzepatide for Weight Reduction in Chinese Adults With Obesity

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 12 P.M. ET, FRIDAY, MAY 31, 2024

Media advisory: The full study and editorials are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.9217?guestAccessKey=83007825-a985-4c21-a783-852d03c8295c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053124

 

About The Study: In Chinese adults with obesity or overweight, once-weekly injection with tirzepatide 10 mg or 15 mg resulted in statistically significant and clinically meaningful weight reduction with an acceptable safety profile. 

Corresponding Author: To contact the corresponding author, Xiaoying Li, M.D., email li.xiaoying@zshospital.sh.cn.

 

(doi:10.1001/jama.2024.9217)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Experience of Personal Loss Due to Drug Overdose Among US Adults

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.1262?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053124

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Mediterranean Diet Adherence and Risk of All-Cause Mortality in Women

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 31, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.14322?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Higher adherence to the Mediterranean diet was associated with a 23% lower risk of all-cause mortality in this cohort study. This inverse association was partially explained by multiple cardiometabolic factors. 

Corresponding Author: To contact the corresponding author, Shafqat Ahmad, Ph.D., email shafqat.ahmad@medsci.uu.se.

 

(doi:10.1001/jamanetworkopen.2024.14322)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

USPSTF Recommendation Statement on Interventions to Prevent Falls in Community-Dwelling Older Adults

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10:30 A.M. (ET), TUESDAY, JUNE 4, 2024

Media advisory: To contact the U.S. Preventive Services Task Force, email the Media Coordinator at Newsroom@USPSTF.net or call 301-951-9203. The full report and related articles are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time and all USPSTF articles remain free indefinitely https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8481?guestAccessKey=fb65a169-6db7-4d00-9ee7-c65a46a2fcd3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060424

 

Bottom Line: The U.S. Preventive Services Task Force (USPSTF) recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls. The USPSTF recommends that clinicians individualize the decision to offer multifactorial interventions to prevent falls to community-dwelling adults 65 years or older who are at increased risk for falls. Existing evidence indicates that the overall net benefit of routinely offering multifactorial interventions to prevent falls is small. When determining whether this service is appropriate for an individual, patients and clinicians should consider the balance of benefits and harms based on the circumstances of prior falls, presence of comorbid medical conditions, and the patient’s values and preferences. Falls are the leading cause of injury-related morbidity and mortality among older adults in the U.S. The USPSTF routinely makes recommendations about the effectiveness of preventive care services and this recommendation replaces the 2018 recommendation.

 

(doi:10.1001/jama.2024.8481)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Note: More information about the U.S. Preventive Services Task Force, its process, and its recommendations can be found on the newsroom page of its website.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email mediarelations@jamanetwork.org.

No Comments

Filed under:

The Integration of Clinical Trials With the Practice of Medicine

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, JUNE 3, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.4088?guestAccessKey=4a0bd782-2ede-46b2-9f99-e85030413468&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060324

 

About The Study: This article discusses the need for better integration of clinical trials and health care delivery enterprises. 

Corresponding Author: To contact the corresponding author, Derek C. Angus, M.D., M.P.H., email angusdc@pitt.edu.

 

(doi:10.1001/jama.2024.4088)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

COVID-19 Vaccination and Cardiopulmonary Events After Acute Coronary Syndromes

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13946?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this secondary analysis of a randomized clinical trial, patients who received at least one COVID-19 vaccine dose after acute coronary syndromes had similar rates of the primary composite end point and major adverse cardiovascular events (MACE) compared with unvaccinated patients. However, retrospective studies have demonstrated a short-term reduction in MACE risk after COVID-19 vaccination. 

Corresponding Author: To contact the corresponding author, Henrique Andrade R. Fonseca, Ph.D., email henrique.fonseca@einstein.br.

 

(doi:10.1001/jamanetworkopen.2024.13946)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Trends in Diagnosed PTSD and Acute Stress Disorder in College Students

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13874?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=053024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this serial cross-sectional study including a national sample of U.S. college students, researchers found a notable increase in the prevalence of posttraumatic stress disorder (PTSD) and acute stress disorder, rising by 4.1 percentage points and 0.5 percentage points from 2017 to 2022, respectively. These trends highlight the escalating mental health challenges among college students, which is consistent with recent research reporting a surge in psychiatric diagnoses. Factors contributing to this rise may include pandemic-related stressors (e.g., loss of loved ones) and the effect of traumatic events (e.g., campus shootings, racial trauma). 

Corresponding Author: To contact the corresponding author, Yusen Zhai, Ph.D., email yzhai@uab.edu.

 

(doi:10.1001/jamanetworkopen.2024.13874)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.6695?guestAccessKey=eb10ccd7-9ab0-4ae2-894d-978a28e0451f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=053024

 

About The Study: In this study, 10 years after diagnosis, 49% of men remained free of progression or treatment, less than 2% developed metastatic disease, and less than 1% died of their disease. Later progression and treatment during surveillance were not associated with worse outcomes. These results demonstrate active surveillance as an effective management strategy for patients diagnosed with favorable-risk prostate cancer. 

 

Quote from corresponding author Lisa F. Newcomb, Ph.D.:

“Our study showed that using active surveillance that includes regular PSA exams and prostate biopsies is a safe and effective management strategy for favorable risk prostate cancer.

“An important finding was that adverse outcomes such as recurrence or metastasis do not seem worse in people treated after several years of surveillance versus one year of surveillance, alleviating concern about losing a window of curability.

“We hope that this study encourages the national acceptance of active surveillance instead of immediate treatment for prostate cancer.”

 

Contact information for Lisa F. Newcomb, Ph.D.: email Kat Wynn at kwynn@fredhutch.org.

 

(doi:10.1001/jama.2024.6695)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Isotretinoin for Acne in Transgender and Gender-Diverse Individuals Receiving Masculinizing Hormone Therapy

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.1420?guestAccessKey=f62e6e0c-189a-42e6-960f-6a5813e7cffa&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052924

No Comments

Filed under:

Adolescent and Adult Transitions From Major Depressive Disorder to Bipolar Disorder

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.1133?guestAccessKey=280543a2-0511-456b-9778-5ff175f3eb3a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052924

No Comments

Filed under:

Ransomware Attacks, ED Visits and Inpatient Admissions in Targeted and Nearby Hospitals

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7752?guestAccessKey=387346ff-a796-48f0-bdc9-b3d2fcccde6c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052924

 

About The Study: This study found a temporary decrease in emergency department (ED) visits and inpatient admissions in hospitals targeted by ransomware attacks and a temporary increase in ED visits in unattacked nearby hospitals in California, suggesting that the consequences of such attacks are broader than the targeted hospitals. 

Corresponding Author: To contact the corresponding author, Rahi Abouk, Ph.D., email aboukr@wpunj.edu.

 

(doi:10.1001/jama.2024.7752)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Sweetened Beverage Tax Implementation and Change in Body Mass Index Among Children in Seattle

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13644?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The results of this study suggest that the sweetened beverage tax in Seattle may be associated with a small but reasonable reduction in body mass index (BMI) among children living in Seattle compared with children living in nearby nontaxed areas who were receiving care within the same health care systems. Taken together with existing studies in the U.S., these results suggest that sweetened beverage taxes may be an effective policy for improving children’s BMI. Future research should test this association using longitudinal data in other U.S. cities with sweetened beverage taxes. 

Corresponding Author: To contact the corresponding author, Jessica C. Jones-Smith, Ph.D., email jjoness@uw.edu.

 

(doi:10.1001/jamanetworkopen.2024.13644)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Abortion Provision and Delays to Care in a Clinic Network in Washington State After Dobbs

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13847?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study provide a detailed picture of changes in abortion provision and delays to care after Dobbs in a state bordering a total ban state. In this study, more people traveled from out of state to receive care and in-state patients sought care a week later in gestation. These findings can inform interventions and policies to improve access for all seeking abortion care. 

Corresponding Author: To contact the corresponding author, Taylor Riley, Ph.D., M.P.H., email striley@uw.edu.

 

(doi:10.1001/jamanetworkopen.2024.13847)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Algorithmic Content Recommendations on a Video-Sharing Platform Used by Children

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13855?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this study of video recommendations for search terms popular with children, thumbnails contained problematic and attention-capturing designs including violent, stereotyped, and frightening themes. Research is needed to understand how children respond to thumbnail designs and whether such designs influence the quality of content children consume. 

Corresponding Author: To contact the corresponding author, Jenny Radesky, M.D., email jradesky@med.umich.edu.

 

(doi:10.1001/jamanetworkopen.2024.13855)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Mobile Mindfulness Intervention for Psychological Distress Among Intensive Care Unit Survivors

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.0823?guestAccessKey=374cab2e-5ea3-471c-8bae-497b9b09e496&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052824

No Comments

Filed under:

Household Water Lead and Hematologic Toxic Effects in Chronic Kidney Disease

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.0904?guestAccessKey=9dd9b616-a925-47e2-842c-f8818012b31a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052824

No Comments

Filed under:

Early-Life Circumstances and Racial Disparities in Cognition Among Older Adults in the US

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.1132?guestAccessKey=3f08f953-1302-4ce4-b78a-7b209ace9324&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052824

No Comments

Filed under:

Patterns of Adverse Childhood Experiences and Neurocognitive Development

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1318?guestAccessKey=16b3d725-801b-474e-8ede-fa002e542eef&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052824

No Comments

Filed under:

Financial Burden of Health Care in the Privately Insured US Population

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 28, 2024

Media advisory: The full study and editor’s note are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.1464?guestAccessKey=501f4b1f-d0e4-4a58-88e7-aa38973a9655&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052824

 

About The Study: In this national cross-sectional study of privately insured U.S. families, inflation-adjusted health care spending increased from 2007 to 2019, largely owing to increasing contributions to premiums. Annual financial medical burden increased significantly, both overall and among low-income and higher-income families. Mean financial medical burden was more than 26% of postsubsistence income for low-income families, compared with approximately 6% for higher-income families.

Corresponding Author: To contact the corresponding author, Rishi K. Wadhera, M.D., M.P.P., M.Phil., email rwadhera@bidmc.harvard.edu.

 

(doi:10.1001/jamainternmed.2024.1464)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Early vs Late Anticoagulation in Minor, Moderate, and Major Ischemic Stroke With Atrial Fibrillation

Posted by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, MAY 28, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.1450?guestAccessKey=5dc6a50b-242a-4ec9-afd4-3ebf3d96a1be&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052824

 

About The Study: The treatment effect of early direct oral anticoagulant initiation did not differ in people with minor, moderate, or major stroke assessed by brain imaging. Early treatment was not associated with a higher rate of adverse events, especially symptomatic intracranial hemorrhage, for any infarct size, including major stroke.

Corresponding Author: To contact the corresponding author, Urs Fischer, M.D., M.Sc., email urs.fischer@insel.ch.

 

(doi:10.1001/jamaneurol.2024.1450)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Air and Noise Pollution Exposure in Early Life and Mental Health From Adolescence to Young Adulthood

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 28, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12169?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Early-life air and noise pollution exposure were prospectively associated with three common mental health problems (psychotic experiences, depression, and anxiety) from adolescence to young adulthood in this longitudinal cohort study. There was a degree of specificity in terms of pollutant-timing-outcome associations. Interventions to reduce air and noise pollution exposure (e.g., clean air zones) could potentially improve population mental health. Replication using quasi-experimental designs is now needed to shed further light on the underlying causes of these associations. 

Corresponding Author: To contact the corresponding author, Joanne B. Newbury, Ph.D., email joanne.newbury@bristol.ac.uk.

 

(doi:10.1001/jamanetworkopen.2024.12169)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Mortality Risk Among Women With Premenstrual Disorders in Sweden

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 28, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13394?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this matched cohort study suggest that women with premenstrual disorders are not at increased risk of early death overall. However, the risk was elevated among young women and for death by suicide. This supports the importance of careful follow-up for young patients and highlights the need to develop suicide prevention strategies for all women with premenstrual disorders. 

Corresponding Author: To contact the corresponding author, Marion Opatowski, Ph.D., email marion.opatowski@ki.se.

 

(doi:10.1001/jamanetworkopen.2024.13394)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Trust and 2024 Public Priorities for the CDC and State Health Departments

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0862?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052424

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Preterm and Early-Term Delivery After Heat Waves in 50 US Metropolitan Areas

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 24, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12055?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Preterm and early-term birth rates increased after heat waves, particularly among socioeconomically disadvantaged subgroups in this cohort study. Extreme heat events have implications for perinatal health. 

Corresponding Author: To contact the corresponding author, Lyndsey A. Darrow, Ph.D., email ldarrow@unr.edu.

 

(doi:10.1001/jamanetworkopen.2024.12055)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Sociodemographic Heterogeneity in the Associations of Social Isolation With Mortality

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 24, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13132?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Social isolation was associated with increased risks of all-cause, cardiovascular diseases, and malignant neoplasm mortality, with associations varying across populations. This study fills an important gap in research on social isolation, emphasizing its varied associations across demographic and socioeconomic groups. 

Corresponding Author: To contact the corresponding author, Atsushi Nakagomi, M.D., Ph.D., email anakagomi0211@gmail.com.

 

(doi:10.1001/jamanetworkopen.2024.13132)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

COVID-19 Admission Rates and Changes in Care Quality in US Hospitals

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 24, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.13127?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052424

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study, COVID-19 surges were associated with declines in hospital quality, highlighting the importance of identifying and implementing strategies to maintain care quality during periods of high hospital use. 

Corresponding Author: To contact the corresponding author, Giacomo Meille, Ph.D., email giacomo.meille@ahrq.hhs.gov.

 

(doi:10.1001/jamanetworkopen.2024.13127)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.1242?guestAccessKey=e50ef5af-cfa3-4e7c-920a-c78ee77cccf1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052324

No Comments

Filed under:

Mandibular Advancement vs Combined Airway and Positional Therapy for Snoring

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2024.1035?guestAccessKey=a2c801a7-fa62-4f53-9517-3212ad7ed761&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052324

No Comments

Filed under:

Accuracy of Salivary Circulating Tumor Human Papillomavirus DNA in Detecting Oropharyngeal Cancer

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2024.1067?guestAccessKey=b722b654-4761-43a5-b6a6-2cfdcd942665&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052324

No Comments

Filed under:

Early Access to First-Seizure Clinics, Subsequent Outcomes, and Factors Associated With Attendance

Posted by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 2:30 A.M. (ET), THURSDAY, MAY 23, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at the Australian and New Zealand Association of Neurologists Annual Scientific Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.1187?guestAccessKey=0fbbf434-5941-4e22-a91b-dc873a3edbd1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052324

 

About The Study: The results of this cohort study suggest that first-seizure clinic (FSC) attendance, particularly early attendance, was associated with reduced rates of subsequent hospital utilization. This knowledge may support adequately resourcing FSCs to improve equitable, timely access. Future study directions include assessing interventions that may support FSC attendance for at-risk groups.

Corresponding Author: To contact the corresponding author, Emma Foster, M.B.B.S.(Hons), Ph.D., email emma.foster@monash.edu.

 

(doi:10.1001/jamaneurol.2024.1187)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Hypertension and Kidney Function After Living Kidney Donation

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10 A.M. ET, THURSDAY, MAY 23, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8523?guestAccessKey=71fafc80-66b5-4525-bc88-2dbd5af0ad65&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052324

 

About The Study: In this cohort study of living kidney donors and nondonors with the same follow-up schedule, the risks of hypertension and albuminuria were not significantly different. After the initial drop in estimated glomerular filtration rate (eGFR) from nephrectomy, donors had a slower mean rate of eGFR decline than nondonors but were more likely to have an eGFR between 30 and 60 mL/min/1.73 m2 at least once in follow-up. 

Corresponding Author: To contact the corresponding author, Amit X. Garg, M.D., Ph.D., email amit.garg@lhsc.on.ca.

 

(doi:10.1001/jama.2024.8523)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Kidney Transplant Outcomes From Deceased Donors Who Received Dialysis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10 A.M. ET, THURSDAY, MAY 23, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8469?guestAccessKey=5db76752-4749-4731-9667-2ebd281f6edb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052324

 

About The Study: Compared with receiving a kidney from a deceased donor who did not undergo dialysis, receiving a kidney from a deceased donor who underwent dialysis prior to kidney donation was associated with a significantly higher incidence of delayed graft function, but no significant difference in graft failure or death at follow-up. 

Corresponding Author: To contact the corresponding author, Chirag R. Parikh, M.D., Ph.D., email chirag.parikh@jhmi.edu.

 

(doi:10.1001/jama.2024.8469)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Effectiveness of a School- and Primary Care–Based HPV Vaccination Intervention

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 23, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.11938?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052324

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cluster randomized trial, within the context of the late COVID-19 pandemic period and limited school and general practitioner participation, at-school human papillomavirus (HPV) vaccination significantly increased vaccination coverage. The trial did not show a significant effect for training general practitioners and education and motivation, although it may be observed after more time has elapsed after the intervention. 

Corresponding Author: To contact the corresponding author, Morgane Michel, Ph.D., email morgane.michel@aphp.fr.

 

(doi:10.1001/jamanetworkopen.2024.11938)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prenatal Exposure to Chemical Mixtures and Metabolic Syndrome Risk in Children

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, MAY 23, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12040?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052324

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this cohort study suggest that prenatal exposure to endocrine-disrupting chemical mixtures may be associated with adverse metabolic health in children. Given the pervasive nature of endocrine-disrupting chemicals and the increase in metabolic syndrome, these findings hold substantial public health implications. 

Corresponding Author: To contact the corresponding author, Martine Vrijheid, Ph.D., email martine.vrijheid@isglobal.org.

 

(doi:10.1001/jamanetworkopen.2024.12040)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

US Public Health Preparedness and Response to Highly Pathogenic Avian Influenza A(H5N1) Viruses

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 12 P.M. ET, TUESDAY, MAY 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.10116?guestAccessKey=97235608-3017-4f2a-b30c-8486923bab25&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052124

 

About The Study: Public health authorities in nearly all states and territories surveyed reported the ability to monitor and test persons exposed to highly pathogenic avian influenza (HPAI) A(H5N1) virus. However, jurisdictions varied in their capacity to monitor exposed persons, in recommendations for use of antivirals, and in potential use of H5N1 vaccines, if available, among first responders. 

 

Quote from co-author Tim Uyeki, M.D., M.P.H., M.P.P.:

 

“Public and animal health experts and agencies have been preparing for avian influenza outbreaks for 20 years. We have invested in our ability to mitigate risk by testing, preventing, and treating it.

 

“The challenges reported in monitoring exposed persons and differences in antiviral recommendations highlight a need to continue to strengthen and standardize public health preparedness and response to HPAI A(H5N1) viruses in the United States, particularly if additional animal-to-human transmission events are reported. It’s important that as the situation develops, public health agencies and authorities continue to work together to guide process improvements to ensure preparedness and consistency in response to future exposures.”

 

Contact information for Tim Uyeki, M.D., M.P.H., M.P.P.: email Jasmine Reed at jreed@cdc.gov

 

(doi:10.1001/jama.2024.10116)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Transmission of Mental Disorders in Adolescent Peer Networks

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.1126?guestAccessKey=77db5a33-85ba-4b33-b47f-d704d07709bd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052224

 

About The Study: The findings of this study suggest that mental disorders might be transmitted within adolescent peer networks. More research is required to elucidate the mechanisms underlying the possible transmission of mental disorders. 

Corresponding Author: To contact the corresponding author, Jussi Alho, Ph.D., email jussi.alho@helsinki.fi.

 

(10.1001/jamapsychiatry.2024.1126)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Firearm Homicide Demographics Before and After the COVID-19 Pandemic

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12946?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this study, death by firearm homicide was concentrated among Black individuals ages 15 to 24 before, during, and subsequent to the COVID-19 pandemic, implying that there are likely to be social and structural conditions that contribute to these racial disparities. 

Corresponding Author: To contact the corresponding author, Alex R. Piquero, Ph.D., email axp1954@miami.edu.

 

(doi:10.1001/jamanetworkopen.2024.12946)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, MAY 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7112?guestAccessKey=0a614c40-2196-4a8c-a050-5957fbbc225a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052224

 

About The Study: Between 2020 and 2023, the number of adolescents and young adults with glucagon-like peptide-1 receptor agonist (GLP-1RA) dispensing increased substantially. In contrast, the number with dispensing of other drugs decreased. Increases in GLP-1RA dispensing were greatest for females, highlighting the importance of educating patients and prescribers on sex-specific safety risks (e.g., concerns during pregnancy). 

 

Quote from corresponding author Joyce M. Lee, M.D., M.P.H.:

“Little is known about the use of GLP-1 RA medications like Wegovy or Ozempic in younger patients. We found that there was a 594% increase in GLP-1 RA medication dispensing between 2020-2023 among adolescents and young adults, highlighting the importance of studying the long-term safety and effectiveness of these medications.

 

“Increases in GLP-1RA dispensing were more pronounced among females than among males. In 2023, 60.0% of adolescents, and 76.4% of young adults dispensed medications were female. This disproportionate dispensing may represent a societal bias towards weight in females and may have implications for the long-term health of girls and women.”

 

Contact information for Joyce M. Lee, M.D., M.P.H.: email joyclee@med.umich.edu.

 

(doi:10.1001/jama.2024.7112)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Socioeconomic Status Transition Throughout Life and Risk of Dementia

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, MAY 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12303?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

  

About The Study: This cohort study of Japanese older adults identified that upward and downward socioeconomic status transitions were associated with risk of dementia and the length of dementia-free periods over the lifespan. The results may be useful to understand the association between social mobility and healthy longevity. 

Corresponding Author: To contact the corresponding author, Hiroyasu Iso, Ph.D., email iso@pbhel.med.osaka-u.ac.jp.

 

(doi:10.1001/jamanetworkopen.2024.12303)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Variations by State in Firearm Suicide Among US Children and Young Adults, 2016-2021

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.1128?guestAccessKey=5603ef88-e57e-4355-88a8-18360ee969dc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

No Comments

Filed under:

Bisoprolol in Patients With COPD at High Risk of Exacerbation

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, MAY 19, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8771?guestAccessKey=d4543ce8-c594-44e0-805b-44a020c965ab&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

 

About The Study: Among people with chronic obstructive pulmonary disease (COPD) at high risk of exacerbation, treatment with the β1-selective β-blocker bisoprolol did not reduce the number of self-reported COPD exacerbations requiring treatment with oral corticosteroids, antibiotics, or both.

Quote from corresponding author Graham Devereux, M.D.:

“People with COPD are at increased risk of cardiovascular conditions that benefit from treatment with beta-blockers. However, there is a well-documented reluctance for physicians to prescribe beta-blockers for people with cardiovascular disease and COPD.

“These findings will help physicians and patients with COPD assess the risks and benefits of using bisoprolol to treat cardiovascular disease.”

 

Contact information for Graham Devereux, M.D.: email graham.devereux@lstmed.ac.uk.

 

(doi:10.1001/jama.2024.8771)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Acetaminophen for Prevention and Treatment of Organ Dysfunction in Critically Ill Patients With Sepsis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, MAY 19, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8772?guestAccessKey=1b8c1ae9-3edc-4366-be12-3cf2610d148d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

 

About The Study: In critically ill sepsis patients, treatment with intravenous acetaminophen for 5 days was safe but did not improve the primary end point of days alive and free of any organ support (dialysis, assisted ventilation, and vasopressors) to day 28 compared with placebo.  

Corresponding Author: To contact the corresponding author, Lorraine B. Ware, M.D., email Lorraine.ware@vumc.org.

 

(doi:10.1001/jama.2024.8772)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Survival Benefit Associated With Participation in Clinical Trials of Anticancer Drugs

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 10 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study, editorial and Viewpoint are linked to this news release. This study is being released to coincide with presentation at the Society for Clinical Trials Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.6281?guestAccessKey=d9f07766-1e0a-40a7-b69b-c448469ffc17&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

 

About The Study: Many studies suggest a survival benefit for cancer trial participants. However, these benefits were not detected in studies using designs addressing important sources of bias and confounding. Pooled results of high-quality studies are not consistent with a beneficial effect of trial participation on its own.

 

Quote from corresponding author Jonathan Kimmelman, Ph.D.:

 

“Many physicians, policymakers, patient advocates, and research sponsors believe patients have better outcomes when they participate in trials, even if they are in the comparator arm. Educational materials for patients often encourage patients to consider the better care they might receive in trials. As a member of various review committees, I hear this said all the time. Yet evidence of such a ‘participation effect’ is lacking.

“Many studies have looked at the ‘participation effect’ for patients with cancer. If you pool them altogether, it looks like cancer patients in trials do live longer than patients outside them. But if you restrict analysis to studies that control for various sources of confound (for example, the fact that trials tend to enroll younger and healthier patients) or bias (many studies of participation benefit are probably never published) those survival benefits disappear.

“Our findings provide reassurance that inability to enroll in a cancer trial doesn’t disadvantage a patient, at least in terms of survival. Our findings can help patients (and physicians) focus their consent discussions on the most relevant and evidence-based benefits of trial participation: the prospects of advancing the care of future patients.”

 

Contact information for Jonathan Kimmelman, Ph.D.: email jonathan.kimmelman@mcgill.ca.

 

(doi:10.1001/jama.2024.6281)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Effect of Sleep Restriction on Adolescent Cognition by Adiposity

Posted by Jim Michalski

JAMA Neurology

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 20, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2024.1332?guestAccessKey=e6f39acb-146d-41ad-b9ae-5f7000613f06

 

About The Study: Adolescents with overweight or obesity may be more vulnerable to negative cognitive effects following sleep restriction. Improved sleep hygiene and duration in this group may positively impact their cognitive health. 

Corresponding Author: To contact the corresponding author, Aaron D. Fobian, Ph.D., email afobian@uabmc.edu.

 

(doi:10.1001/jamaneurol.2024.1332)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Pamrevlumab for Idiopathic Pulmonary Fibrosis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 9 A.M. ET, SUNDAY, MAY 19, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the American Thoracic Society 2024 International Conference.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8693?guestAccessKey=822f31af-46d7-4bed-b18f-275b80c4c704&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051924

 

About The Study: Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in forced vital capacity from baseline to week 48. 

 

Quote from corresponding author, Ganesh Raghu, M.D.:

 

“Current treatment with the two drugs approved by regulatory agencies for the treatment of idiopathic pulmonary fibrosis (IPF) merely slow the rate of lung function decline and are associated with adverse events that affect medication adherence. Because of the high mortality rates that are associated with IPF, the need for efficacious treatments that meaningfully improve patients’ feeling and function, as well as survival, is evident and unmet.

“This well-conducted, multinational phase 3 trial undertaken to assess the efficacy and safety of pamrevlumab for patients with IPF failed to confirm it. Despite the disappointment with the negative results, the success lies in the patients who participated in this trial and adhered to the protocol amid all the challenges and hurdles of the COVID-19 pandemic and lessons gleaned will help better design of future trials.”

Contact information for Ganesh Raghu, M.D.: email graghu@uw.edu.

 

(doi:10.1001/jama.2024.8693)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Racial and Ethnic Inequities in Cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.12050?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=052024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study of patients with cancer and SARS-CoV-2, racial and ethnic inequities existed in treatment delays and discontinuations throughout the pandemic; however, the disproportionate burden among racially and ethnically minoritized patients with cancer varied across SARS-CoV-2 waves. These inequities may lead to downstream adverse impacts on cancer mortality among minoritized adults in the United States.

Corresponding Author: To contact the corresponding author, Jessica Y. Islam, Ph.D., M.P.H., email jessica.islam@moffitt.org.

 

(doi:10.1001/jamanetworkopen.2024.12050)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

A Comparison of Ukrainian Hospital Services and Functions Before and During the Russia-Ukraine War

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0901?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051724

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Measuring Primary Care Spending in the US by State

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.0913?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051724

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Ultraprocessed Food Consumption and Cardiometabolic Risk Factors in Children

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, MAY 17, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.11852?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=051724

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study suggest that high ultraprocessed food (UPF) consumption in young children is associated with adiposity and other cardiometabolic risk factors, highlighting the need for public health initiatives to promote the replacement of UPFs with unprocessed or minimally processed foods. 

Corresponding Author: To contact the corresponding author, Nancy Babio, Ph.D., email nancy.babio@urv.cat.

 

(doi:10.1001/jamanetworkopen.2024.11852)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Oropharyngeal Cancer Staging Health Record Extraction Using AI

Posted by Jim Michalski

JAMA Otolaryngology–Head & Neck Surgery

EMBARGOED FOR RELEASE: 4:15 P.M. (ET), THURSDAY, MAY 16, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at the American Head And Neck Society Annual Meeting at Combined Otolaryngology Spring Meetings 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaotolaryngology/fullarticle/10.1001/jamaoto.2023.1201?guestAccessKey=d00c9284-3b48-4557-9d6f-7f4450d46156&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051624

 

About The Study: The results of this study suggest that artificial intelligence may be associated with enhanced patient care and oncological decision-making in patients with oropharyngeal squamous cell carcinoma through detection of localized versus advanced cancer stages. Further model refinement and external validation with electronic health records at different institutions are necessary to improve algorithm accuracy and clinical applicability.

Corresponding Author: To contact the corresponding author, Antoine Eskander, M.D., email antoine.eskander@mail.utoronto.ca.

 

(doi:10.1001/jamaoto.2023.1201)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Sex Differences in Primary Care–Based Chronic Kidney Disease Management

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 2:45 P.M. ET, THURSDAY, MAY 16, 2024

Media advisory: The full study is linked to this news release. The study is being released to coincide with presentation at the Society of General Internal Medicine annual meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.8914?guestAccessKey=2d474e45-94e6-4eb2-8419-e90ef782683d&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051624

 

About The Study: This study found significant sex differences in primary care–based chronic kidney disease management among patients at a care network affiliated with an academic medical center in the U.S., with females overall receiving worse care than males. Though many differences were of small magnitude, the disparity deserves further examination. 

Corresponding Author: To contact the corresponding author, Jorge A. Rodriguez, M.D., email jarodriguez1@partners.org.

 

(doi:10.1001/jama.2024.8914)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome

Posted by Jim Michalski

JAMA Dermatology

EMBARGOED FOR RELEASE: 5 P.M. (ET), FRIDAY, MARCH 17, 2024

Media advisory: The full study is linked to this news release. This study is being released to coincide with presentation at the Society for Investigative Dermatology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.1804?guestAccessKey=f652fe63-9ce2-4011-aa0c-1a820be55a1f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051724

 

About The Study: This study found that BRCA1-associated protein (BAP1) tumor predisposition syndrome was associated with a high rate of nail abnormalities consistent with onychopapillomas (a benign tumor of the nail) in adult carriers of the disease. Findings suggest that this novel cutaneous sign may facilitate detection of the syndrome in family members who are at risk and patients with cancers associated with BAP1 given that multiple onychopapillomas are uncommon in the general population and may be a distinct clue to the presence of a pathogenic germline variant in the BAP1 gene.

Corresponding Authors: To contact the corresponding authors, email Edward W. Cowen, M.D., M.H.Sc. (cowene@mail.nih.gov) and Raffit Hassan, M.D. (hassanr@mail.nih.gov).

 

(doi:10.1001/jamadermatol.2024.1804)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Federal Trade Commission Actions on Prescription Drugs, 2000-2022

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, MAY 20, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.5737?guestAccessKey=b5df0e55-79b2-4af8-9a64-87a6674156de&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052024

 

About The Study: The Federal Trade Commission (FTC) brought about one enforcement action and three merger actions per year against pharmaceutical manufacturers from 2000-2022, pursuing a small fraction of the estimated misconduct and consolidation in the pharmaceutical marketplace. Although the FTC faces substantial legal and practical limitations, important tools remain untested, including a rule defining “unfair methods of competition,” that may allow it to more effectively prevent repetitive patterns of anticompetitive behavior. 

Corresponding Author: To contact the corresponding author, Aaron S. Kesselheim, M.D., J.D., M.P.H., email akesselheim@bwh.harvard.edu.

 

(doi:10.1001/jama.2024.5737)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under: